CTNNB1 and hepatocellular carcinoma: We treated mice with either PBS, LNP-CTRL, or LNP-CTNNB1 utilizing a similar LNP frequency and dosage scheme as in Figure S1a, yet applied this to our T41A-mutant-β-catenin-Nrf2 (β-N) model (Figure S1g), which we have previously shown to represent 9–12% of all human HCC.27 Following treatment, we observed a decrease in liver weights and LW/BW ratio in LNP-CTNNB1 treated mice (Figure S1h–i), yet no appreciable difference in liver serum biochemistries (Figure S1j).